<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517201</url>
  </required_header>
  <id_info>
    <org_study_id>iNCDSS-2</org_study_id>
    <nct_id>NCT04517201</nct_id>
  </id_info>
  <brief_title>AI-Assisted Insulin Titration System on Inpatients Glucose Control</brief_title>
  <official_title>Study to Assess Artificial Intelligence-Assisted Insulin Titration System on Inpatients Glucose Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-labeled, parallel group, randomized controlled trial to access&#xD;
      the effect and safety of the Artificial Intelligence Assisted Insulin Titration System&#xD;
      (iNCDSS) in patients with Type 2 Diabetes Mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As one of the most common treatments for diabetes inpatients, insulin regimens often vary due&#xD;
      to different physicians. Since 2016, Zhongshan Hospital has set up the Internet-based glucose&#xD;
      management system (iGMS) to monitor plasma glucose of diabetes patients, and further set up&#xD;
      an Artificial Intelligence Assisted Insulin Titration System (iNCDSS) to recommend insulin&#xD;
      regime in 2019. Previous single-center clinical trial (NCT04053959) have demonstrated the&#xD;
      efficacy and safety of iNCDSS in glycemic management in patients with type 2 diabetes.&#xD;
&#xD;
      This multi-center study enrolls 120 patients with Type 2 Diabetes from 20 wards of Zhongshan&#xD;
      Hospital who are on treatment with insulin for at least 3 months. They are randomly allocated&#xD;
      into 2 groups at a ratio of 1:1 after screening for the inclusion and exclusion criteria.&#xD;
      Patients in the Intervention group (AI group) receive insulin regimen set by iNCDSS and&#xD;
      patients in Control group receive insulin regimen recommended by endocrinologists.&#xD;
&#xD;
      This study will be conducted in the Department of Endocrinology, Zhongshan Hospital,Fudan&#xD;
      University and consist of a 7-day intervention period. Patient allocation will be stratified&#xD;
      by HbA1c, BMI and previous total insulin doses. The primary endpoint is the fasting plasma&#xD;
      glucose level after the 7-days trial period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting plasma glucose of T2D patients</measure>
    <time_frame>After 7-day intervention</time_frame>
    <description>Fasting plasma glucose of T2D patients by self-monitoring of bloodglucose (SMBG) in both groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Well-controlled rate of fasting blood glucose</measure>
    <time_frame>During 7-day intervention</time_frame>
    <description>The well-controlled rate of blood glucose is defined as proportion of the time of sensor glucose measurements in targeted range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia</measure>
    <time_frame>During 7-day intervention</time_frame>
    <description>The hypoglycemia is defined as blood glucose level less than 3.9mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total insulin dose</measure>
    <time_frame>During 7-day intervention</time_frame>
    <description>The total insulin dose is defined as daily insulin dose.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>AI group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iGMS+iNCDSS group (Artificial intelligence assisted insulin titration system group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iGMS+routine treatment group (Physicians decided insulin titration group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iNCDSS based insulin regime</intervention_name>
    <description>Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).</description>
    <arm_group_label>AI group</arm_group_label>
    <other_name>iGMS + iNCDSS based insulin regime</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician based insulin regime</intervention_name>
    <description>Patients of this group will receive the insulin regime recommended by professional endocrinologists.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>iGMS + routine insulin treatment regime</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women aged 18-99 years old;&#xD;
&#xD;
          -  Inpatients who had been diagnosed with type 2 diabetes;&#xD;
&#xD;
          -  Subjects who are on treatment with insulin for at least 3 months;&#xD;
&#xD;
          -  HbA1c: 7.0%-10.0%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who were diagnosed with T1D, gestational diabetes or other specific types of&#xD;
             diabetes.&#xD;
&#xD;
          -  Subjects with acute complications of diabetes such as ketoacidosis or hyperglycemic&#xD;
             hyperosmolar state;&#xD;
&#xD;
          -  Patients with severe cardiac, hepatic, renal or general diseases;&#xD;
&#xD;
          -  Subjects that are, in the judgement of the investigator, unlikely to comply with the&#xD;
             protocol.&#xD;
&#xD;
          -  Absence of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Bian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Bian</last_name>
    <phone>+8613681976102</phone>
    <email>bianhuaer@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Bian, chief physician</last_name>
      <email>bianhuaer@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Bian</last_name>
      <phone>+8613681976102</phone>
      <email>bianhuaer@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.html?layout=hcopy</url>
    <description>IDF DIABETES ATLAS-7TH EDITION.</description>
  </link>
  <reference>
    <citation>Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA. 2013 Sep 4;310(9):948-59. doi: 10.1001/jama.2013.168118.</citation>
    <PMID>24002281</PMID>
  </reference>
  <reference>
    <citation>Wang T, Xu Y, Xu M, Wang W, Bi Y, Lu J, Dai M, Zhang D, Ding L, Xu B, Sun J, Zhao W, Jiang Y, Wang L, Li Y, Zhang M, Lai S, Wang L, Ning G. Awareness, treatment and control of cardiometabolic disorders in Chinese adults with diabetes: a national representative population study. Cardiovasc Diabetol. 2015 Feb 26;14:28. doi: 10.1186/s12933-015-0191-6.</citation>
    <PMID>25848699</PMID>
  </reference>
  <reference>
    <citation>Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ershow AG, Fradkin J, Inzucchi SE, Kosiborod M, Nelson RG, Patel MJ, Pignone M, Quinn L, Schauer PR, Selvin E, Vafiadis DK; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research, and the American Diabetes Association. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation. 2015 Aug 25;132(8):691-718. doi: 10.1161/CIR.0000000000000230. Epub 2015 Aug 5. Review.</citation>
    <PMID>26246173</PMID>
  </reference>
  <reference>
    <citation>Rawshani A, Rawshani A, Gudbj√∂rnsdottir S. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017 Jul 20;377(3):300-301. doi: 10.1056/NEJMc1706292.</citation>
    <PMID>28723317</PMID>
  </reference>
  <reference>
    <citation>Contreras I, Vehi J. Artificial Intelligence for Diabetes Management and Decision Support: Literature Review. J Med Internet Res. 2018 May 30;20(5):e10775. doi: 10.2196/10775. Review.</citation>
    <PMID>29848472</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Hua Bian</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>iNCDSS</keyword>
  <keyword>T2D</keyword>
  <keyword>AI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

